Table 2.
Subgroup analyses based on characteristics of included studies for thromboembolism in patients after AF ablation.
| Subgroup | Variable | Number of studies | OR (95%CI) |
|---|---|---|---|
| Study design | Prospective | 11 | 0.69 (0.46,1.03) |
| Retrospective | 5 | 0.60 (0.25,1.43) | |
| Region | Asian | 4 | 0.64 (0.37,1.11) |
| Non-Asian | 12 | 0.65 (0.35,1.20) | |
| OAC type | Warfarin | 10 | 0.57 (0.28,1.14) |
| Warfarin or NOACs | 6 | 0.70 (0.42,1.17) | |
| Whether switch to antiplatelet drugs | Switch to antiplatelet drugs | 12 | 0.54 (0.31,0.94) |
| Not switch to antiplatelet drugs | 4 | 0.96 (0.43,2.13) | |
| Follow-up duration | <3 years | 9 | 0.60 (0.38,0.95) |
| ≥3 years | 7 | 0.75 (0.35,1.62) |
AF = atrial fibrillation; CI = confidence interval; OAC = oral anticoagulant; OR = odds ratio; NOACs = non-vitamin K antagonist oral anticoagulants.